Comparison of self-expanding transcatheter heart valves for aortic stenosis: the multicentre, randomised, controlled, non-inferiority DOUBLE-CHOICE trial - PubMed
3 days ago
- #Aortic Stenosis
- #TAVI
- #Randomized Trial
- The DOUBLE-CHOICE trial compared the self-expanding ACURATE neo2 valve to Evolut PRO/PRO+/FX valves in TAVI for severe aortic stenosis.
- At 30 days, the primary composite endpoint occurred in 15.4% of ACURATE neo2 patients vs. 30.4% in Evolut patients, establishing non-inferiority (p<0.001).
- Permanent pacemaker implantation was significantly lower with ACURATE neo2 (11.2%) than Evolut (26.5%).
- Rates of moderate/severe prosthetic valve regurgitation were low and similar between groups (1.3% vs. 1.7%).
- The study concluded ACURATE neo2 is non-inferior to Evolut valves in selected anatomies, driven by lower pacemaker rates.